Biomakers key facts
- Operator of a precision medicine center intended to develop personalized drugs.
- It has raised $20.0M across 1 recorded rounds; the latest was Early Stage VC ($5.9M) in Jan 2024.
- Notable investors include Google for Startups, Labcorp Venture Fund, Sonen Capital, Covance, Endeavor Argentina — 12 tracked in total.
- Biomakers has filed 2 Form Ds with the SEC since 2024, most recently Feb 2025 ($2.4M sold to 5 investors).
- Status: Privately Held (backing).
Who backs Biomakers
12+- ·The complete investor list: 12 names
- ·Watch Biomakers: the Monday email on marks, rounds and moves
Biomakers funding rounds
1 roundsHow much has Biomakers raised?
Biomakers has raised $20 million in total; 1 of its rounds is on record. The largest on record was a $5.9 million early-stage round in Jan 2024.
Biomakers has filed 2 Form Ds with the SEC since 2024, most recently in Feb 2025 ($2.4 million sold to 5 investors).
Biomakers investors
12 investors are on record for Biomakers, including Google for Startups, Labcorp Venture Fund, Sonen Capital and Covance. The early-stage round in Jan 2024 drew 7 investors.
About Biomakers
Operator of a precision medicine center intended to develop personalized drugs. The company leverages genetic sequencing and in-depth bioinformatics analysis to provide differential genetic counseling services for all available trials and transforms genomic and molecular information into therapeutic analysis, enabling healthcare professionals to make treatment decisions based on scientific data available for their patients.
- Sector
- Healthcare
- HQ
- Buenos Aires, Argentina
- Founded
- 2014
- Employees
- 77
- Website
- biomakers.io/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Biomakers doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.